Webinar: Clinical Trials for, and despite, COVID-19

October 27, 2020

IDDI Complimentary Webinar on characteristics of Covid-19 trials and impact of the pandemic on clinical trials


The current SARS-CoV-2-induced coronavirus 2019 (COVID-19) pandemic has called for urgent design and implementation of clinical trials against this potentially life-threatening infection. The pandemic has also had a tremendous impact on ongoing clinical trials for all other indications. In both cases, the crisis has highlighted several limitations that currently exist and hinder a more agile and pragmatic, but at the same time ethically and scientifically sound, clinical-trials enterprise.


  •  the key characteristics of COVID-19 trials, particularly with regard to trial-design features such as trial mechanics (including factorial and multi-stage designs, as well as platform trials), outcome assessment, and other important methodological issues.
  •  the impact the pandemic is having on clinical trials in several fields, including oncology and cardiology.
  • practical issues pertaining to trial design and conduct, including for data capture, data management, statistical analysis, and patient follow-up, all of which affected by the current crisis.


Marc Buyse, ScD, Chief Scientific Officer at IDDI.

  • He holds a ScD in biostatistics from the Harvard School of Public Health (Boston, MA).
  • He is the founder of the International Drug Development Institute (IDDI) and of CluePoints, two biostatistical service organizations based in the US and Europe.
  • He is interested in clinical trial design, meta-analysis, validation of biomarkers and surrogate endpoints, statistical methods in oncology, statistical detection of errors and fraud, statistical monitoring of clinical trials, and medical data sharing (http://publicationslist.org/marc.buyse).

Everardo Saad, MD: Medical Director at IDDI

  • He has nearly 20 years of experience in Medical Oncology and clinical trial designs.
  • He graduated in Medicine and trained in Internal Medicine in Sao Paulo, and did his fellowship in Medical Oncology at the University of Texas M.D. Anderson Cancer Center, in Houston.
  • After practicing for several years, he shifted his professional career towards education and research in Medical Oncology, and has a special interest in clinical trial methodology, the assessment of endpoints, and the development of novel therapies for cancer patients.

PRESENTATION WEBINAR: Clinical Trials for, and despite, COVID-19

To access the presentation of this on-demand webinar, please fill out this form.

    By submitting this form, you agree to receiving commercial electronic messages such as e-mails from IDDI. For more info, please visit our Privacy Policy. You can unsubscribe at any time by clicking the 'unsubscribe' button at the foot of any e-mail communication from IDDI.

    I authorize IDDI to use my data to contact me for commercial purposes.More information